Loading...
Market
What will be Zevra Therapeutics' stock price performance by the end of 2024?
3
Resolution / Starting Odds
Increase by 20% or more • 25%
Increase by less than 20% • 25%
Remain about the same • 25%
Decrease • 25%
Publicly available stock price data from financial news websites or stock exchanges
Story
FDA Approves Zevra's Miplyffa for Niemann-Pick Disease Type C, $150 Million Voucher
Sep 20, 2024, 01:40 PM
The U.S. Food and Drug Administration (FDA) has approved Zevra Therapeutics' drug, arimoclomol, also known as Miplyffa, for the treatment of Niemann-Pick disease type C (NPC), a rare and fatal genetic disorder. This approval marks the first oral medication to receive FDA approval for NPC. In addition, Zevra Therapeutics is now eligible to receive a Priority Review Voucher worth approximately $150 million. The approval was announced on September 20, 2024, ahead of the NDA PDUFA date of September 21, 2024.
View original story
Similar markets
Increase by 0-10% • 25%
Increase by 10-20% • 25%
Increase by more than 20% • 25%
Decrease or no change • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
More than 30% • 25%
Increase by more than 20% • 25%
Decrease by more than 20% • 25%
Remain within ±20% • 25%
Other • 25%
Below $25 • 25%
$25 - $50 • 25%
$50 - $75 • 25%
Above $75 • 25%
Increase by more than 20% • 25%
Increase by up to 20% • 25%
Decrease by up to 20% • 25%
Decrease by more than 20% • 25%
Less than $50 million • 25%
$50 million - $100 million • 25%
$100 million - $150 million • 25%
More than $150 million • 25%
Decrease by 5% or more • 25%
Change between -5% and 5% • 25%
Increase between 5% and 10% • 25%
Increase by 10% or more • 25%
Less than $20 • 25%
$20 to $30 • 25%
$30 to $40 • 25%
More than $40 • 25%
Above $25 • 25%
$20 - $25 • 25%
$15 - $20 • 25%
Below $15 • 25%